Chromium
Phase 3Small molecule
Chromium is one of 7 small molecule programs targeting Polycystic Ovarian Syndrome. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Polycystic Ovarian Syndrome
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Femara
NovartisPhase 3
Farxiga
AstraZenecaPhase 3
Clomid
FerringPhase 3
L-Arginine
Mario Negri Institute for Pharmacological ResearchPhase 3
Myoinositol
SSohag University
Phase 3
Chromium
FFayoum University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovarian Syndrome1 trial
Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
Not yet recruiting·—·Phase 3·NCT06405243·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Chromium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFayoum University